Conţinutul numărului revistei |
Articolul precedent |
Articolul urmator |
1044 7 |
Ultima descărcare din IBN: 2023-09-12 18:54 |
SM ISO690:2012 REVENCO, Ninel, CRACEA (DRUŞCA), Angela, CRACEA (DRUŞCA), Angela, SCRIPNIC, Elena, PLETOSU, I.. Tratamentul biologic în artrita juvenilă idiopatică
. In: Analele Ştiinţifice ale USMF „N. Testemiţanu”, 2012, nr. 5(13), pp. 233-238. ISSN 1857-1719. |
EXPORT metadate: Google Scholar Crossref CERIF DataCite Dublin Core |
Analele Ştiinţifice ale USMF „N. Testemiţanu” | ||||||
Numărul 5(13) / 2012 / ISSN 1857-1719 | ||||||
|
||||||
Pag. 233-238 | ||||||
|
||||||
Descarcă PDF | ||||||
Rezumat | ||||||
Juvenile idiopathic arthritis (JIA) in a systemic form is a chronic multisystemic inflammatory disease, characterized by clinical and laboratory signs of undetermined joint inflammation genesis, lasting at least 6 weeks, the onset being before 16 years and needs specialized support. An important role in the evolution of the systemic form of JIA occupies interleukin-6 (IL-6), which is one of the central cytokines. IL-6 hyperproduction contributes to the development of fever and thrombocytosis, stimulates the production of acute phase,s proteins inflammation (C reactive protein, fibrinogen, haptoglobin), also inhibits albumin and transferrin, stimulates hepsidin,s secretion. Thus, the inhibition of IL-6,s activity is present in the treatment of systemic variant of JIA. For this purpose the drug Tocilizumab was synthesized. Drug Tocilizumab is a humanized IgG1 monoclonal anti-human interleukin-6 receptor. Tocilizumab binds specifically to both IL-6 soluble and membrane receptors. |
||||||
|